Eli Lilly and Company
LLY
$989.87
$22.882.37%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 11.42% | 18.90% | -1.38% | 105.16% | -37.43% |
| Total Depreciation and Amortization | -13.10% | 24.62% | -1.78% | 3.35% | -4.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -179.64% | -120.61% | 299.59% | -143.65% | 1,016.84% |
| Change in Net Operating Assets | 54.71% | -404.10% | 153.39% | 32.73% | -51.27% |
| Cash from Operations | 65.38% | -63.51% | 186.24% | 85.29% | -32.66% |
| Capital Expenditure | 8.67% | -21.99% | -23.02% | -12.39% | -0.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -848.03% | 79.69% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -269.70% | 58.35% | -150.73% | 92.52% | -334.16% |
| Cash from Investing | -39.75% | 6.05% | -62.55% | 45.28% | -74.54% |
| Total Debt Issued | 887,600.00% | -100.00% | -- | -100.00% | 6,461,100.00% |
| Total Debt Repaid | -249,900.00% | 99.99% | -596.14% | 144.60% | -160.78% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -56.26% | -112.92% | -2.30% | 42.32% | 41.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.05% | -0.02% | 0.13% | -0.07% | -15.25% |
| Other Financing Activities | -2,254.58% | 16.89% | 0.66% | 95.57% | -1,394.55% |
| Cash from Financing | -20.54% | -642.15% | 142.65% | -190.21% | 711.97% |
| Foreign Exchange rate Adjustments | 199.85% | -311.67% | -88.49% | 108.71% | 130.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.30% | -139.33% | 2,170.35% | 261.49% | -72.58% |